Can combo drugs penetrate tough brain tumors? new study seeks answers
NCT ID NCT04391595
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether a combination of two drugs (LY3214996 and abemaciclib) can reach brain tumors in people with recurrent glioblastoma, a type of aggressive brain cancer. About 42 participants took the drugs before surgery to remove their tumor, and researchers measured drug levels in the tumor tissue and spinal fluid. The goal was to see if the drugs penetrate the brain and potentially slow tumor growth.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GBM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chandler Regional Medical Center
Chandler, Arizona, 85224, United States
-
HonorHealth Scottsdale Osborn Medical Center
Scottsdale, Arizona, 85251, United States
-
St. Joseph's Hospital and Medical Center
Phoenix, Arizona, 85013, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?
- Can adding lenvatinib to standard care outsmart a tough brain cancer?
- A simple lotion duo may shield skin from Tumor-Treating fields